Home

Earlier today, the MAPRx Coalition submitted to the Centers for Medicare & Medicaid Services (CMS) comments regarding the implementation of the Medicare Drug Price Negotiation Program (MDPNP) for initial price applicability year 2026.

The Coalition appreciates the opportunity to comment on how Medicare intends to negotiate with
pharmaceutical manufacturers for lower prices on selected high-cost drugs. MAPRx believes... Read more

The Annual Open Enrollment for Medicare prescription drug coverage (Part D) is October 15, 2022 – December 7, 2022 for coverage beginning January 1, 2023. Plans make changes to benefits and costs, and there are also new plans in many areas of the country. Changes to the Part D benefit as a whole may also impact how beneficiaries move through... Read more

A new report commissioned by the MAPRx Coalition examines the growing clinical evidence for coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in Medicare Part D.

As the medical community’s understanding of disease states evolves, MAPRx is calling on the Part D program to evolve alongside it to ensure it is providing... Read more